
-
Forest Champions League dreams hit after Brentford defeat
-
'Resilient' Warriors aim to close out Rockets in bruising NBA playoff series
-
US expects Iran talks but Trump presses sanctions
-
Baffert returns to Kentucky Derby, Journalism clear favorite
-
Top Trump security official replaced after chat group scandal
-
Masked protesters attack Socialists at France May Day rally
-
Mumbai eliminate Rajasthan from IPL playoff race with bruising win
-
McDonald's profits hit by weakness in US market
-
Rio goes Gaga for US singer ahead of free concert
-
New research reveals where N. American bird populations are crashing
-
Verstappen late to Miami GP as awaits birth of child
-
Zelensky says minerals deal with US 'truly equal'
-
Weinstein lawyer says accuser sought payday from complaint
-
Police arrest more than 400 in Istanbul May Day showdown
-
Herbert named head coach of Canada men's basketball team
-
'Boss Baby' Suryavanshi falls to second-ball duck in IPL
-
Shibutani siblings return to ice dance after seven years
-
300,000 rally across France for May 1, union says
-
US-Ukraine minerals deal: what we know
-
Top Trump official ousted after chat group scandal: reports
-
Schueller hat-trick sends Bayern women to first double
-
Baudin in yellow on Tour de Romandie as Fortunato takes 2nd stage
-
UK records hottest ever May Day
-
GM cuts 2025 outlook, projects up to $5 bn hit from tariffs
-
Thousands of UK children write to WWII veterans ahead of VE Day
-
Top Trump official exiting after chat group scandal: reports
-
Madrid Open holder Swiatek thrashed by Gauff in semis
-
Sheinbaum says agreed with Trump to 'improve' US-Mexico trade balance
-
US veteran convicted of quadruple murder to be executed in Florida
-
UK counter terrorism police probe Irish rappers Kneecap
-
S. Korea crisis deepens with election frontrunner retrial, resignations
-
Trump administration releases report critical of youth gender care
-
IKEA opens new London city centre store
-
Police deploy in force for May Day in Istanbul, arrest hundreds
-
Syria Druze leader condemns 'genocidal campaign' against community
-
Prince Harry to hear outcome of UK security appeal on Friday
-
Microsoft raises Xbox prices globally, following Sony
-
US stocks rise on Meta, Microsoft ahead of key labor data
-
Toulouse injuries mount as Ramos doubtful for Champions Cup semi
-
Guardiola glad of Rodri return but uncertain if he'll play in FA Cup final
-
Ruud sails past Medvedev into Madrid Open semis
-
'Not a commodity': UN staff rally over deep cuts
-
Flintoff proud as Afghan refugee protege plays for Lancashire second team
-
Peruvian cardinal accused of abuse challenges late pope's sanction
-
Trans women barred from women's football by English, Scottish FAs
-
Oil prices drop, stocks diverge amid economic growth fears
-
Israel brings fire near Jerusalem 'under control', reopens roads
-
Lopetegui appointed coach of Qatar
-
UK counter-terrorism unit probes rappers Kneecap but music stars back band
-
Yamal heroics preserve Barca Champions League final dream

International Stem Cell Corporation Announces 2024 Fourth Quarter and Year-End Results
SAN DIEGO, CA / ACCESS Newswire / March 31, 2025 / International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, today provided a business update and announced fourth quarter and year-end financial results for the period ending on December 31, 2024.
FY 2024 Financial Highlights:
Revenues increased to $9.09 million in 2024, an increase of 17% compared to $7.79 million in 2023.
Combined operating income for the year ended December 31, 2024, from our two wholly owned subsidiaries, Lifeline Cell Technology and Lifeline Skin Care, increased to $2.39 million, an increase of 29%, compared to $1.85 million in 2023.
Loss from operations decreased to $68,000 for the year ended December 31, 2024, a decrease of 90%, compared to $663,000 in 2023.
"2024 has been a successful year for International Stem Cell Corporation, marked by both strong financial performance and continued progress in our clinical trial. Our revenue growth, coupled with a significant reduction in operational losses, underscores the strength of our business model and the demand for our biomedical products. At the same time, we remain committed to advancing our pioneering ISC-hpNSC® program, building upon the promising interim results observed in our Phase 1 clinical trial. Looking ahead, we are focused on leveraging these achievements to drive further growth, accelerate our research, and enhance value for our shareholders," stated Andrey Semechkin, Ph.D., CEO and Co-Chairman of ISCO.
About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (www.lifelineskincare.com).
For more information, please visit http://internationalstemcell.com/ or contact: [email protected]
To subscribe to receive ongoing corporate communications, please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0
To like our Facebook page or follow us on Twitter for company updates and industry related news, visit: www.facebook.com/InternationalStemCellCorporation and www.twitter.com/intlstemcell
Safe harbor statement
Statements pertaining to anticipated developments and company achievements, expected clinical studies (including results and ongoing evaluation of the phase 1 clinical trial), and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, regulatory approvals, need and ability to obtain capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the Company's business, particularly those mentioned in the cautionary statements found in the Company's Securities and Exchange Commission filings. The Company disclaims any intent or obligation to update forward-looking statements.
International Stem Cell Corporation and Subsidiaries
Consolidated Balance Sheets
(In thousands, except share and par value data)
December 31, | ||||||
2024 | 2023 | |||||
Assets | ||||||
Current assets: | ||||||
Cash | $ | 1,230 | $ | 1,588 | ||
Accounts receivable, net | 1,058 | 574 | ||||
Inventories | 1,149 | 1,263 | ||||
Prepaid expenses and other current assets | 123 | 96 | ||||
Total current assets | 3,560 | 3,521 | ||||
Non-current inventories | 252 | 266 | ||||
Property and equipment, net | 257 | 215 | ||||
Intangible assets, net | 721 | 800 | ||||
Right-of-use assets | 352 | 557 | ||||
Deposits and other assets | 31 | 31 | ||||
Total assets | $ | 5,173 | $ | 5,390 | ||
Liabilities, Redeemable Convertible Preferred Stock and Stockholders' Deficit | ||||||
Current liabilities: | ||||||
Accounts payable | $ | 186 | $ | 364 | ||
Accrued liabilities | 527 | 485 | ||||
Operating lease liabilities, current | 330 | 276 | ||||
Advances | 250 | 250 | ||||
Related party note payable | 3,395 | 3,457 | ||||
Total current liabilities | 4,688 | 4,832 | ||||
Operating lease liabilities, net of current portion | 115 | 445 | ||||
Total liabilities | 4,803 | 5,277 | ||||
Commitments and contingencies (Note 11) | ||||||
Series D redeemable convertible preferred stock, $0.001 par value; 50 shares authorized; 43 shares issued and outstanding; liquidation preference of $4,300 at December 31, 2024 and 2023 | 4,300 | 4,300 | ||||
Stockholders' Deficit: | ||||||
Non-redeemable convertible preferred stock, $0.001 par value; 10,004,310 and 10,004,310 shares authorized; 5,254,310 and 5,254,310 shares issued and outstanding; liquidation preference of $9,811 and $9,796 at December 31, 2024 and 2023, respectively | 5 | 5 | ||||
Common stock, $0.001 par value; 120,000,000 shares authorized; 8,004,389 shares issued and outstanding at December 31, 2024 and 2023 | 8 | 8 | ||||
Additional paid-in capital | 106,742 | 106,276 | ||||
Accumulated deficit | (110,685 | ) | (110,476 | ) | ||
Total stockholders' deficit | (3,930 | ) | (4,187 | ) | ||
Total liabilities, redeemable convertible preferred stock and stockholders' deficit | $ | 5,173 | $ | 5,390 |
International Stem Cell Corporation and Subsidiaries
Consolidated Statements of Operations
(In thousands, except share and per share data)
Year Ended December 31, | ||||||
2024 | 2023 | |||||
Product sales | $ | 9,085 | $ | 7,789 | ||
Operating expenses: | ||||||
Cost of sales | 3,764 | 3,181 | ||||
General and administrative | 3,516 | 3,514 | ||||
Selling and marketing | 1,216 | 1,246 | ||||
Research and development | 657 | 511 | ||||
Total operating expenses | 9,153 | 8,452 | ||||
Loss from operations | (68 | ) | (663 | ) | ||
Other income (expense): | ||||||
Employee retention credit | - | 663 | ||||
Interest expense | (145 | ) | (139 | ) | ||
Other income, net | 4 | 8 | ||||
Total other (expense) income, net | (141 | ) | 532 | |||
Net loss | (209 | ) | (131 | ) | ||
Net loss per common share, basic and diluted | $ | (0.03 | ) | $ | (0.02 | ) |
Weighted-average common shares used to compute net loss per share, basic and diluted | 8,004,389 | 8,004,389 |
Contacts:
International Stem Cell Corporation
Russell A. Kern, PhD, Executive VP
Phone: 760-940-6383
Email: [email protected]
SOURCE: International Stem Cell Corporation
View the original press release on ACCESS Newswire
A.Mahlangu--AMWN